Amgen tops profit estimates on sales of arthritis, bone drugs

AMGEN INC. saw its profits beat out estimates in the fourth quarter, while its net income dropped 16 percent to $788 million.
Posted 1/24/13

SAN FRANCISCO - Amgen Inc., the world’s largest biotechnology companies, reported fourth-quarter profit that beat analyst estimates as sales of arthritis and bone drugs rose.

Net income declined 16 percent to $788 million, or $1.01 a share, from $934 million, or $1.08 a share, a year earlier, the Thousand Oaks, California-based company said today in a statement. Earnings, excluding some items, of $1.40 a share topped by 1 cent the average of 10 analyst estimates compiled by Bloomberg. Revenue rose 11 percent to $4.42 billion.

Amgen is looking for new products and acquisitions to boost revenue as its former core anemia business declines. Last month the company agreed to buy DeCode Genetics Inc., a genetics research company, for $415 million. Amgen last year also acquired Micromet Inc. for $1.16 billion to add an experimental leukemia drug, signed a development deal with London-based AstraZeneca Plc and boosted its cancer-market presence through sales of Xgeva, a bone drug that reduces fractures.

“We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally,” Amgen Chief Executive Officer Robert Bradway said in the statement.

Amgen shares have declined 7.9 percent since Dec. 12 when they reached their highest value ever at $90.17. The stock gained 34 percent in 2012, it’s best annual increase since 1999, as investors rewarded the company for its buyback program, dividend and sales increase.

Amgen forecast 2013 earnings, excluding some items, from $6.85 to $7.15 a share. Analysts had expected $7 a share, the average of 26 estimates compiled by Bloomberg.

PBN Hosted

Two Great Programs...One Great Event. PBN's Annual Celebration of Growth and Innovation is now underway. 2014 applications are now available. Deadline August 1st.
  • 40 Under Forty
    We're almost sold out. The 10th Anniversary of 40 Under Forty, and PBN is planni ...
  • Healthiest Employers
    Save the date - August 14th - at the Providence Marriott for the 3rd annual Heal ...
Purchase Data
Book of Lists
Book of Lists cover
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.
Data icons
Data can be purchased as single lists, in either Excel or PDF format; the entire database of the published book, in Excel format; or a printed copy of the Book of Lists.
  • Purchase an e-File of a single list
  • Purchase an e-File of the entire Book of Lists database
  • Purchase a printed copy of the Book of Lists
    Latest News